Toripalimab, a novel therapy has been discovered for the treatment of nasopharyngeal carcinoma by Junshi Biosciences.
Toripalimab, the first anti-PD-1 monoclonal antibody developed for the treatment of Nasopharyngeal carcinoma (NPC) is the first to receive breakthrough designation in China. NPC is one among the most common malignant tumors seen in the people of China. Compared with the world average, the number of people affected with NCP is more in China.
Earlier patients with nasopharyngeal carcinoma would have a good therapeutic effect with 90% can be cured or be tumor-free for a long time lacking specific clinical symptoms.
US Food and Drug Administration (FDA) has granted the Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma (NPC) is a malignant tumor which generally occurs in the mucosal epithelium of the nasopharynx, mainly in the parietal and lateral walls of the nasopharynx, particularly in the pharyngeal recess.
